Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...1314151617181920212223...401402»
  • ||||||||||  Journal:  GDF5 as a rejuvenating treatment for age-related neuromuscular failure. (Pubmed Central) -  Nov 3, 2024   
    In addition, in human muscle biopsies, we found the same age-related alterations than those observed in mice and improved by GDF5 and reproduced its major effects on human cells, suggesting this treatment as efficient in humans. Overall, these data provide a foundation to examine the curative potential of GDF5 drug in clinical trials for sarcopenia and, eventually, other neuromuscular diseases.
  • ||||||||||  Improving delivery of exercise in oncology: an implementation science approach (Arena 1B) -  Nov 3, 2024 - Abstract #COSA2024COSA_269;    
    Implementation science is the scientific study of strategies to promote the use of evidence-based practices in routine clinical care. I will explore common barriers to exercise delivery and provide implementation science-informed solutions for success.
  • ||||||||||  Review, Journal:  Experimental models as a tool for research on sarcopenia: a narrative review. (Pubmed Central) -  Nov 2, 2024   
    We will summarize the literature and present relevant experimental models in terms of their advantages and disadvantages. All of the presented approaches could potentially contribute to the accurate and early diagnosis, follow-up, and possible treatment of sarcopenia.
  • ||||||||||  Review, Journal:  Sarcobesity: new paradigms for healthy aging related to taurine supplementation, gut microbiota and exercise. (Pubmed Central) -  Nov 2, 2024   
    For this reason, further studies are needed that encourage the support of therapeutic management. It is along these lines that we direct the reader to therapeutic approaches that demonstrate important, but still obscure, outcomes in the physiological conditions of sarcobesity, such as the role of taurine in modulating inflammatory and antioxidant mechanisms in muscle and adipose tissue, as well as the management of gut microbiota, able to systemically re-establish the structure and function of the gut-muscle axis, in addition to the merits of physical exercise as an instrument to improve muscular health and lifestyle quality.
  • ||||||||||  Journal, Surgery:  Role of sarcopenia in complex abdominal wall surgery: does it increase postoperative complications and mortality? (Pubmed Central) -  Nov 1, 2024   
    Although sarcopenia does not seem to have an influence on hernia recurrence or the development of postoperative complications, whether local or systemic, in our study sarcopenia is associated with a higher risk of mortality after complex abdominal wall surgery. Nonetheless, with the results obtained in our study, we think that prehabilitation programs before complex AWS is advisable.
  • ||||||||||  Biomarker, Journal:  Associations between serum cystatin C and fall reports in an Elderly population. (Pubmed Central) -  Oct 30, 2024   
    In contrast, Cre and eGFR were not significant after adjustments; SI showed marginal significance (p?=?0.045). Cys C is significantly associated with fall risk in older adults, demonstrating a positive linear relationship with self-reported falls.
  • ||||||||||  Review, Journal, Surgery:  Prognostic value of body composition in oncological visceral surgery (Pubmed Central) -  Oct 29, 2024   
    Rapidly growing evidence shows that body composition parameters, especially reduced muscle mass, are associated with adverse outcomes in cancer patients and have been reported to negatively affect overall survival (OS), disease-free survival (DFS), toxicity associated with chemotherapy and surgical complications. In this article, we summarize the recent literature and present the clinical influence of body composition in oncological visceral diseases.
  • ||||||||||  Journal:  Sarcopenia. (Pubmed Central) -  Oct 29, 2024   
    In this article, we summarize the recent literature and present the clinical influence of body composition in oncological visceral diseases. No abstract available
  • ||||||||||  oltipraz (PMK-N01GI1) / Canopus BioPharma, Pharmaking
    Journal:  Heat exposure promotes sarcopenia via gut microbiota-derived metabolites. (Pubmed Central) -  Oct 29, 2024   
    And Nrf2 activator (Oltipraz) supplementation alleviates muscle atrophy and dysfunction induced by heat exposure. Our findings reveal the detrimental effects of heat exposure on muscle function and provide new strategies for treating sarcopenia.
  • ||||||||||  Review, Journal:  Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives. (Pubmed Central) -  Oct 28, 2024   
    Furthermore, there are numerous insightful studies suggesting additional benefits of TTh, for instance in cardio-renal-metabolic conditions. Specifically, future trials should investigate the role of TTh in improving symptoms and prognosis in various clinical contexts, including sarcopenia, frailty, dyslipidemia, arterial hypertension, diabetes mellitus, fracture risk, heart failure, stable angina, chronic kidney disease, mood disorders, and cognitive dysfunction.